Camp4 Therapeutics Corp (CAMP): Shareholders' Equity
$47.70M
As of 2025-12-31
-$693.0K
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.70M | -24.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $63.14M | n/m | 2026-03-05, Balance as of period end |
| 2023-12-31 | -$123.73M | n/a | 2025-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $47.70M | -24.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $16.80M | -9.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $18.22M | -53.5% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $7.40M | +23.1% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $22.74M | +193.5% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $339.77M | -27.7% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | -$126.24M | n/m |
Compare CAMP, MRKR, CRVO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗